HomeDiovanNovartis restructure marks break from expansion
Posted in Diovan on 17th March 2014

Novartis restructure marks break from expansion
Operating margins have declined for the past two years and another $ 3bn is expected to be knocked off sales this year because of looming generic competition for its Diovan blood pressure treatment and Gleevec cancer drug. In response, Mr Jimenez has …
Read more on Financial Times

Related Post for Sandoz Launches Generic Diovan in the U.S.

Diovan Cleber – Onde esta você
Cardiovascular Anatomy Diovan Valsartan Capsules 2nd PDF
to make FDA OKs Ranbaxy New Jersey plant generic Diovan
Another One Bites the Dust: Diovan patent has expired, but general valsartan Is MIA
Sandoz Launches Generic Diovan in the U.S.